Novo Nordisk invests in new insulin-filling facility
pharmafile | November 4, 2015 | News story | Manufacturing and Production | Denmark, Novo Nordisk, manufacturing, production
Novo Nordisk is investing 2.1 billion Danish Kroner (about £200m) in a new facility in Hillerød, Denmark, which will produce diabetes and obesity treatments.
Ground will be broken for the 10,300 square-metre facility, which is expected to be operational in 2019. It will create 450 new production and engineering jobs in Hillerød, where Novo Nordisk already employs 1,900 people.
Incorporating the latest state-of-the-art insulin production technology, the new insulin-filling facility will ensure production capacity for existing and future products within diabetes.
The announcement follows that of strong nine-month results for Novo, particularly in its diabetes products range, where results were driven by the performance of its Victoza (liraglutide) and Levemir (insulin determir) diabetes treatments.
Novo has sought to ramp up production of its diabetes products in recent months. It is investing 500 million Danish Kroner (about £48.8 million) in a new 19,000 square-metre warehouse in Hillerød, Denmark. The warehouse will handle all inbound raw materials for Novo Nordisk’s production in Denmark and will have a capacity of around 17,000 pallets. Novo Nordisk is also building a manufacturing plant in Iran, which will produce FlexPen insulin devices.
“The investment in Hillerød underscores our long-term ambition to create and maintain jobs in Denmark. This year alone we have created 1,000 new jobs in Denmark, of which 500 are in production, primarily in Kalundborg and Hillerød,” says Henrik Wulff, executive vice president and head of product supply at Novo Nordisk.
Established in 1992, the Hillerød site already covers an area of about 1,650,000 square-metres, of which 90,000 is used for production, research and development. The site houses a facility for device R&D and three production facilities: one for moulding and pre-assembly of components, one for filling, assembly and packaging of diabetes finished products and one for the production of active pharmaceutical ingredients for haemophilia products.
Joel Levy
Related Content
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …
Pila Pharma raises SEK 20m to advance new oral obesity treatment
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …
